Vyleesi® product results: 14% growth in prescriptions dispensed over prior quarter – 6 consecutive quarters of double digit growth.
Click here to learn more ›

May 2023

Palatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference

Press Releases / By

–  Results demonstrate melanocortin agonists may represent a new therapeuticavenue to treat diabetic nephropathy –  Open Label Phase 2 clinical study in diabetic kidney disease enrolling patients CRANBURY, N.J., May 30, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the …

Palatin Presents Preclinical Diabetic Nephropathy Data at the International Podocyte Conference Read More »

Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update

Press Releases / By

 May 16, 2023, 07:30 ET  Phase 3 PL9643 Data in Patients with Dry Eye Disease Presented at KOL Event Analysis of Lead-In Population of Initial 120 Patients Showed Statistical Separation for Clinical Efficacy Across Multiple Signs and Symptoms of Dry Eye along with Excellent Patient Safety and Tolerability Final Data Expected Second Half Calendar Year …

Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update Read More »

Palatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023

Press Releases / By

 May 11, 2023, 16:15 ET  CRANBURY, N.J., May 11, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2023 operating results on Tuesday, May 16, 2023, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive …

Palatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023 Read More »

Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference

Press Releases / By

 May 09, 2023, 07:30 ET  –  Preclinical data presented shows PL8177 was found to be efficacious in animal models of inflammatory bowel disease –  Clinical data confirms PL8177 oral formulation is delivered and contained in the colon –  Phase 2 clinical study data readout in 2H2023 CRANBURY, N.J., May 9, 2023 /PRNewswire/ — Palatin Technologies, …

Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference Read More »

Palatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader Webinar

Press Releases / By

 May 08, 2023, 16:04 ET  CRANBURY, N.J., May 8, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today hosted a key opinion leader (KOL) webinar presenting data from the Lead-In population of the ongoing PL9643 MELODY-1 Phase …

Palatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader Webinar Read More »

Scroll to Top